Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Muharrem Muftuoglu

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2019
Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's LymphomaZi-Xun Yan, Li Li, Wen Wang, et al.
Frontiers in Immunology|January 30, 2018
Evidence for B Cell Exhaustion in Chronic Graft-versus-Host DiseaseAhmad Khoder, Abdullah Alsuliman, Rafet Basar, et al.
Blood Cancer Journal|April 23, 2023
Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimeticsBing Z Carter, Po Yee Mak, Wenjing Tao, et al.
Blood Cancer Journal|May 16, 2023
Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimeticsBing Z Carter, Po Yee Mak, Wenjing Tao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2025
Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition With Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild Type Acute Myeloid LeukemiasWeiguo Zhang, Li Li, Muharrem Muftuoglu, et al.
Leukemia|April 4, 2025
CLL cell-derived exosomes alter the immune and hematopoietic systemsIvo Veletic, David M Harris, Uri Rozovski, et al.
Blood Cancer Journal|April 24, 2025
Dual targeting of EZH2 and EZH1 drives exit of leukemia stem cells from quiescence and potentiates chemotherapy in acute myeloid leukemiaHiroki Akiyama, Yuki Nishida, Kyung Hee Chang, et al.
Blood|November 9, 2016
A subset of virus-specific CD161<sup>+</sup> T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AMLAbdullah Alsuliman, Muharrem Muftuoglu, Ahmad Khoder, et al.
Science Advances|November 29, 2023
Enhanced <i>TP53</i> reactivation disrupts <i>MYC</i> transcriptional program and overcomes venetoclax resistance in acute myeloid leukemiasYuki Nishida, Jo Ishizawa, Edward Ayoub, et al.
Blood|July 22, 2016
IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantationAnushruti Sarvaria, Rafet Basar, Rohtesh S Mehta, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2019
Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's LymphomaZi-Xun Yan, Li Li, Wen Wang, et al.
Frontiers in Immunology|January 30, 2018
Evidence for B Cell Exhaustion in Chronic Graft-versus-Host DiseaseAhmad Khoder, Abdullah Alsuliman, Rafet Basar, et al.
Blood Cancer Journal|April 23, 2023
Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimeticsBing Z Carter, Po Yee Mak, Wenjing Tao, et al.
Blood Cancer Journal|May 16, 2023
Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimeticsBing Z Carter, Po Yee Mak, Wenjing Tao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2025
Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition With Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild Type Acute Myeloid LeukemiasWeiguo Zhang, Li Li, Muharrem Muftuoglu, et al.
Leukemia|April 4, 2025
CLL cell-derived exosomes alter the immune and hematopoietic systemsIvo Veletic, David M Harris, Uri Rozovski, et al.
Blood Cancer Journal|April 24, 2025
Dual targeting of EZH2 and EZH1 drives exit of leukemia stem cells from quiescence and potentiates chemotherapy in acute myeloid leukemiaHiroki Akiyama, Yuki Nishida, Kyung Hee Chang, et al.
Blood|November 9, 2016
A subset of virus-specific CD161<sup>+</sup> T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AMLAbdullah Alsuliman, Muharrem Muftuoglu, Ahmad Khoder, et al.
Science Advances|November 29, 2023
Enhanced <i>TP53</i> reactivation disrupts <i>MYC</i> transcriptional program and overcomes venetoclax resistance in acute myeloid leukemiasYuki Nishida, Jo Ishizawa, Edward Ayoub, et al.
Blood|July 22, 2016
IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantationAnushruti Sarvaria, Rafet Basar, Rohtesh S Mehta, et al.
Pageof 3